Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Food and Drug Regulations

Version of section C.04.580 from 2018-04-04 to 2019-06-20:

  •  (1) A fabricator shall not sell Globin Insulin with Zinc unless he

    • (a) has filed with the Minister, in accordance with subsection (2), a submission relating to that preparation, in a form and having a content satisfactory to the Minister;

    • (b) has furnished the Minister with such additional information as the Minister may require; and

    • (c) has received from the Minister a notice that the information contained in the submission is in accordance with the requirements of this section.

  • (2) A submission filed pursuant to subsection (1) shall include at least,

    • (a) for each master lot of insulin or zinc-insulin crystals employed in the manufacture of Globin Insulin with Zinc,

      • (i) protocols of assay of its potency expressed in International Units per cubic centimetre in the case of insulin, and in International Units per milligram in the case of zinc-insulin crystals,

      • (ii) a report of its moisture content in percentage determined by drying to constant weight at 100°C in the case of zinc-insulin crystals, and

      • (iii) reports of assay of its nitrogen content in milligrams and its zinc content in milligrams per 1,000 International Units of insulin;

    • (b) for the master lot of globin hydrochloride used in the preparation of Globin Insulin with Zinc, reports of assay of

      • (i) its nitrogen content in per cent calculated on a dry, ash-free and hydrochloric acid free basis,

      • (ii) its chloride content in per cent calculated as hydrochloride, and

      • (iii) its ash content in percentage;

    • (c) for the components used in the preparation of the trial mixture of Globin Insulin with Zinc, a report on the quantity of

      • (i) insulin in grams, or in International Units,

      • (ii) zinc in grams, or in milligrams, per 1,000 International Units of insulin,

      • (iii) globin hydrochloride in grams or in milligrams, per 1,000 International Units of insulin, and

      • (iv) the volume of the preparation in cubic centimetres or litres;

    • (d) for the trial mixture of Globin Insulin with Zinc,

      • (i) a report of assay of its nitrogen content in milligrams per cubic centimetre or per 1,000 International Units of insulin,

      • (ii) a report of assay of its zinc content in milligrams per cubic centimetre or per 1,000 International Units of insulin,

      • (iii) protocols of the biological reaction showing the retardation of the insulin effect, and

      • (iv) a report on the determination of its pH;

    • (e) for the first finished lot of Globin Insulin with Zinc from each trial mixture of Globin Insulin with Zinc, a report on the amount of each component in the preparation; and

    • (f) for the first filling of the first finished lot of Globin Insulin with Zinc from each trial mixture of Globin Insulin with Zinc,

      • (i) a report of assay of its nitrogen content in milligrams per cubic centimetre or per 1,000 International Units of insulin,

      • (ii) a report of assay of its zinc content in milligrams per cubic centimetre or per 1,000 International Units of insulin, and

      • (iii) a report on the determination of its pH.

      • (iv) [Repealed, SOR/95-203, s. 6]

  • SOR/82-769, s. 4
  • SOR/95-203, s. 6
  • SOR/97-12, s. 61
  • SOR/2018-69, ss. 27, 31(E), 32(F)
Date modified: